CXCL8 and COVID-19: In addition to significantly higher levels of IP-10, IL-8, HGF, and MIP-1β observed among patients with COVID-19 from the primary cohort in comparison to healthy controls, the validation cohort also exhibited significantly greater levels of IL-12, epidermal growth factor (EGF), and IL-2 (fig.